Drug Profile
ALVAC-CEA B7.1
Alternative Names: CEA vaccine; TBC CEALatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA); Therion Biologics
- Developer National Cancer Institute (USA); sanofi-aventis; Therion Biologics
- Class
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 18 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
- 11 Feb 2003 Phase-I clinical trials in stage III Colorectal cancer in Canada (SC)